AARS2 Antibody

What is AARS2 and why is it important in scientific research?

AARS2 is a mitochondrial alanyl-tRNA synthetase that catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Additionally, it performs a crucial editing function to clear mischarged Ser-tRNA^Ala, preventing misincorporation of serine at alanine codons . This enzyme has a canonical length of 985 amino acids with a molecular mass of approximately 107.3 kDa and is localized in the mitochondria . AARS2 has gained significant research interest due to its associations with fatal infantile cardiomyopathy, leukoencephalopathy, and more recently, its potential role as a biomarker in various cancers . Understanding AARS2 function is particularly important because slight decreases in its proofreading activity can result in embryonic lethality in mice, highlighting its critical role in cellular function .

What applications are commonly used with AARS2 antibodies?

Based on commercial antibody data and published literature, AARS2 antibodies are employed in multiple experimental techniques:

When designing experiments, researchers should validate antibody performance in their specific experimental conditions as reactivity can vary between antibodies and suppliers . Additionally, antigen retrieval methods (such as TE buffer pH 9.0 or citrate buffer pH 6.0) should be optimized for IHC applications .

How should AARS2 antibodies be stored and handled to maintain optimal activity?

Most commercial AARS2 antibodies are supplied in a liquid form with PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3 . For optimal storage and handling:

• Store antibodies at -20°C, where they typically remain stable for one year after shipment .

• Aliquoting is generally unnecessary for -20°C storage with glycerol-containing formulations .

• Avoid repeated freeze-thaw cycles, which can cause protein denaturation and loss of antibody activity.

• Some preparations may contain 0.1% BSA for additional stability in smaller (20 μl) sizes .

• When working with the antibody, keep it on ice and return to -20°C promptly after use.

• Prior to use, gently mix the antibody solution without vortexing to maintain antibody integrity.

It is crucial to consult the specific storage recommendations provided by the manufacturer, as formulations may vary between suppliers.

How can researchers validate the specificity of AARS2 antibodies in their experimental systems?

Rigorous validation is essential when working with AARS2 antibodies to ensure experimental reliability:

• Knockdown/Knockout Validation: Use AARS2 siRNA knockdown or CRISPR-Cas9 knockout systems to generate negative controls. In published studies, researchers have used siRNA to knock down AARS2 expression in neonatal rat cardiomyocytes (NRCMs) to validate antibody specificity .

• Western Blot Analysis: Verify a single band at the expected molecular weight (approximately 107-115 kDa) . Multiple bands may indicate degradation products, isoforms, or non-specific binding.

• Tissue Panel Testing: Test the antibody across a panel of tissues with known AARS2 expression levels. AARS2 is widely expressed in many tissue types, with notable expression in cardiac tissue .

• Multi-antibody Approach: Use multiple antibodies targeting different AARS2 epitopes to confirm consistent results.

• Mass Spectrometry Confirmation: For definitive validation, immunoprecipitate AARS2 and confirm its identity using mass spectrometry.

• Recombinant AARS2 Control: Include purified recombinant AARS2 protein as a positive control in immunoblotting experiments.

Patient samples with confirmed AARS2 mutations have shown decreased mt-AlaRS protein levels in skeletal and cardiac muscle, which can serve as valuable controls in certain research contexts .

What methodological considerations are important when using AARS2 antibodies to study mitochondrial dysfunction?

When investigating mitochondrial dysfunction using AARS2 antibodies, several methodological considerations are crucial:

• Subcellular Fractionation: Since AARS2 is localized to mitochondria, proper mitochondrial isolation is essential. Consider using differential centrifugation techniques followed by Percoll gradient purification for high-purity mitochondrial fractions.

• Co-localization Studies: Perform co-immunofluorescence with established mitochondrial markers (e.g., TOMM20, COX IV) to confirm mitochondrial localization of AARS2.

• Functional Assays: Combine antibody-based detection with functional assays that measure:

  • Mitochondrial oxygen consumption rate (OCR), which has been shown to be affected in AARS2-deficient cardiomyocytes

  • Extracellular acidification rate (ECAR), which can indicate metabolic shifts

  • Mitochondrial ROS production using indicators like mtSOX

• RNA Analysis: Complement protein studies with mtRNA analysis, particularly examining mt-tRNA^Ala levels, which have been reported to be decreased in patients with AARS2 mutations .

• Post-translational Modifications: Consider investigating potential post-translational modifications of AARS2 that might affect its function under stress conditions.

• Temporal Analysis: Assess AARS2 dynamics over time following mitochondrial stress induction, as temporal changes may reveal compensatory mechanisms.

Research has shown that AARS2 depletion leads to decreased maximal OCR and ECAR in cardiomyocytes, indicating impaired energy metabolism .

How can AARS2 antibodies be optimally employed in cancer research applications?

Recent studies have identified AARS2 as a potential oncogenic factor and biomarker in various cancers, particularly hepatocellular carcinoma (HCC) . When using AARS2 antibodies in cancer research:

• Expression Profiling: Determine AARS2 expression levels across cancer types and stages, as AARS2 has been found to be dramatically upregulated in multiple cancers .

• Multiplex IHC Protocols: Optimize multiplex immunohistochemistry to simultaneously evaluate AARS2 along with other cancer biomarkers and immune cell markers.

  Sample Protocol:

  • Use sequential tyramide signal amplification for multiple antibodies

  • Include AARS2 (1:100 dilution, Proteintech 22696-1-AP as used in published studies )

  • Antigen retrieval with TE buffer pH 9.0

  • Counterstain with DAPI for nuclear visualization

  • Include appropriate isotype controls

• Functional Studies: Combine antibody detection with functional assays:

  • Cell proliferation assays following AARS2 knockdown (in published studies, AARS2 deficiency inhibited cell proliferation and migration in HCC )

  • Migration/invasion assays to assess metastatic potential

  • Apoptosis assays to determine cell survival dependencies

• Prognostic Evaluation: Correlate AARS2 expression with patient outcomes and treatment responses, as studies suggest AARS2 could serve as a biomarker for prognosis and immunotherapy response .

• Immune Microenvironment Analysis: Investigate relationships between AARS2 expression and immune cell infiltration, as published research has explored correlations between AARS2 expression and immune cell activity using ssGSEA method .

• Drug Response Prediction: Assess AARS2 expression in relation to drug sensitivity, as studies have identified potential drugs targeting AARS2-expressing cancer cells .

What experimental approaches are recommended for investigating AARS2 in cardiac pathologies?

AARS2 has significant implications in cardiac pathologies, particularly in fatal infantile cardiomyopathy and myocardial ischemia . Recommended experimental approaches include:

• Animal Models:

  • Cardiac-specific AARS2 conditional knockout models (AARS2 cKO) using α-MHC-MerCreMer system

  • Cardiac-specific AARS2 overexpression models (AARS2 Tg/+) for gain-of-function studies

  • Myocardial infarction (MI) models to study the protective role of AARS2 in ischemia

• Echocardiography: Assess cardiac function parameters including:

  • Ejection fraction (EF)

  • Fractional shortening (FS)

  • Left ventricular end-diastolic dimension (LVEDD)

  • Left ventricular end-systolic dimension (LVESD)

• Cardiomyocyte Isolation and Culture:

  • Primary neonatal rat cardiomyocytes (NRCMs) for in vitro studies

  • Hypoxia and reoxygenation (H/R) models to simulate ischemia/reperfusion injury

• Molecular Analyses:

  • Assess apoptotic markers (Bcl-2, BAX) in relation to AARS2 expression

  • Measure lactate dehydrogenase (LDH) as a marker of cardiac injury

  • Evaluate mitochondrial ROS production using appropriate indicators

• Metabolism Studies:

  • Investigate the relationship between AARS2 and cardiac energy metabolism

  • Explore AARS2's role in modulating PKM2-mediated energy metabolism in cardiomyocytes

Research has demonstrated that AARS2 overexpression protects against myocardial ischemia, with improved cardiac function (increased EF and FS) post-MI in AARS2 Tg/+ mice compared to controls .

What are common technical challenges when using AARS2 antibodies and how can they be addressed?

When working with patient samples with AARS2-related disorders, researchers should be aware that mt-AlaRS protein levels may be markedly decreased or undetectable, requiring sensitive detection methods and appropriate controls .

How should researchers interpret contradictory results from AARS2 antibody experiments?

When faced with contradictory results:

• Antibody Validation: Re-validate antibody specificity using knockdown/knockout controls. Studies have shown that siRNA knockdown of AARS2 can significantly reduce protein levels, providing a useful negative control .

• Isoform Consideration: Determine if contradictory results might reflect detection of different AARS2 isoforms or post-translationally modified forms.

• Context Dependence: Assess whether differences in experimental contexts (cell types, disease states, stress conditions) might explain divergent results. For example, AARS2 expression patterns may differ between cancer tissues and normal tissues .

• Quantification Methods: Evaluate different quantification approaches, including normalization strategies, that might lead to different interpretations.

• Biological vs. Technical Variation: Distinguish biological phenomena from technical artifacts by increasing biological and technical replicates.

• Multi-omics Integration: Integrate antibody-based results with orthogonal approaches such as RNA-seq, proteomics, or functional assays to resolve contradictions.

• Literature Review: Compare results with published findings, considering that AARS2-related diseases show phenotypic heterogeneity that might explain conflicting observations .

For resolving experimental contradictions, patient-derived samples with genetically confirmed AARS2 variants can provide valuable benchmarks for antibody performance and expected biological effects .

How can AARS2 antibodies contribute to biomarker development in cancer and other diseases?

Recent research has established AARS2 as a potential biomarker in several disease contexts:

• Cancer Biomarker Development:

  • AARS2 is upregulated in multiple cancers, potentially due to copy number alterations

  • It shows promise as a biomarker for both prognosis and immunotherapy response prediction

  • Protocols combining AARS2 immunodetection with other cancer biomarkers could enhance diagnostic accuracy

• Cardiomyopathy Biomarker Applications:

  • Fatal infantile cardiomyopathy associated with specific AARS2 variants (e.g., p.Arg580Trp and p.Arg592Trp)

  • AARS2 antibodies could help stratify cardiac phenotypes in mitochondrial disease patients

• Leukoencephalopathy Detection:

  • AARS2-related leukoencephalopathy with ovarian failure presents distinct AARS2 variant patterns

  • Combined imaging and AARS2 protein analysis might improve diagnostic accuracy

• Methodological Approaches:

  • Develop standardized IHC and Western blot protocols for consistent AARS2 quantification

  • Establish scoring systems for AARS2 expression in tissue sections

  • Create multiplex panels including AARS2 and other disease-specific markers

• Clinical Translation Strategies:

  • Validate AARS2 as part of multi-biomarker panels in large patient cohorts

  • Develop tissue microarray approaches for high-throughput AARS2 screening

  • Explore liquid biopsy applications to detect AARS2 in circulating tumor cells or exosomes

AARS2 biomarker development should consider the specific variants and expression patterns associated with different disease phenotypes, as the same gene can manifest in distinct clinical presentations based on the specific mutations involved .

What are the latest methodological advances in studying AARS2's role in mitochondrial function?

Recent advances in studying AARS2's mitochondrial functions include:

• Real-time Mitochondrial Respiration Analysis:

  • Seahorse XF technology to simultaneously measure OCR and ECAR in AARS2-modified cells

  • Integration with mitochondrial stress tests to assess reserve capacity and proton leak

• Advanced Imaging Techniques:

  • Super-resolution microscopy to visualize AARS2 localization within mitochondrial subcompartments

  • Live-cell imaging to track AARS2 dynamics during mitochondrial stress responses

• Genetic Manipulation Approaches:

  • CRISPR-Cas9-based AARS2 knockout and knockin models

  • Inducible expression systems to study temporal aspects of AARS2 function

  • Cardiac-specific conditional knockout and transgenic overexpression models

• Protein-Protein Interaction Studies:

  • Proximity labeling techniques to identify AARS2 interaction partners

  • Co-immunoprecipitation combined with mass spectrometry to characterize AARS2 complexes

• Metabolic Tracing:

  • Stable isotope tracing to elucidate AARS2's impact on metabolic pathways

  • Integration with targeted metabolomics to assess specific metabolic alterations

• Single-Cell Approaches:

  • Single-cell proteomics to analyze cell-to-cell variability in AARS2 expression

  • Correlation of AARS2 levels with mitochondrial heterogeneity

Recent work has demonstrated that AARS2 plays a critical role in protecting cardiomyocytes from ischemic pressure through fine-tuning PKM2-mediated energy metabolism, opening new avenues for investigating mitochondrial adaptations during stress .